PortfoliosLab logoPortfoliosLab logo
SRRK vs. CCCC
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SRRK vs. CCCC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Scholar Rock Holding Corporation (SRRK) and C4 Therapeutics, Inc. (CCCC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SRRK achieves a -0.57% return, which is significantly lower than CCCC's 87.96% return.


SRRK

1D
-1.13%
1M
-9.49%
YTD
-0.57%
6M
-3.20%
1Y
27.96%
3Y*
84.27%
5Y*
8.97%
10Y*

CCCC

1D
-6.75%
1M
21.69%
YTD
87.96%
6M
41.34%
1Y
107.51%
3Y*
1.04%
5Y*
-38.85%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

SRRK vs. CCCC - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
SRRK
Scholar Rock Holding Corporation
-0.57%1.92%129.89%107.73%-63.57%-48.82%215.33%
CCCC
C4 Therapeutics, Inc.
87.96%-46.94%-36.28%-4.24%-81.68%-2.81%29.97%

Correlation

The correlation between SRRK and CCCC is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.37

Correlation (All Time)
Calculated using the full available price history since Oct 5, 2020

0.35

The correlation between SRRK and CCCC shifts across timeframes, from 0.19 (1 year) to 0.37 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

SRRK:

$5.57B

CCCC:

$452.61M

EPS

SRRK:

-$3.49

CCCC:

-$1.18

PB Ratio

SRRK:

20.20

CCCC:

1.93

Total Revenue (TTM)

SRRK:

$0.00

CCCC:

$28.71M

Gross Profit (TTM)

SRRK:

-$1.27M

CCCC:

$26.90M

EBITDA (TTM)

SRRK:

-$394.71M

CCCC:

-$107.31M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SRRK vs. CCCC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SRRK
SRRK Risk / Return Rank: 5959
Overall Rank
SRRK Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
SRRK Sortino Ratio Rank: 6161
Sortino Ratio Rank
SRRK Omega Ratio Rank: 5757
Omega Ratio Rank
SRRK Calmar Ratio Rank: 6060
Calmar Ratio Rank
SRRK Martin Ratio Rank: 6161
Martin Ratio Rank

CCCC
CCCC Risk / Return Rank: 7575
Overall Rank
CCCC Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
CCCC Sortino Ratio Rank: 8080
Sortino Ratio Rank
CCCC Omega Ratio Rank: 7474
Omega Ratio Rank
CCCC Calmar Ratio Rank: 7676
Calmar Ratio Rank
CCCC Martin Ratio Rank: 7373
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SRRK vs. CCCC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Scholar Rock Holding Corporation (SRRK) and C4 Therapeutics, Inc. (CCCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SRRKCCCCDifference
Sharpe ratioReturn per unit of total volatility

-0.64

Sortino ratioReturn per unit of downside risk

-1.02

Omega ratioGain probability vs. loss probability

1.14

1.24

-0.10

Calmar ratioReturn relative to maximum drawdown

0.81

2.08

-1.27

Martin ratioReturn relative to average drawdown

1.92

4.02

-2.10

SRRK vs. CCCC - Sharpe Ratio Comparison

The current SRRK Sharpe Ratio is 0.43, which is lower than the CCCC Sharpe Ratio of 1.07. The chart below compares the historical Sharpe Ratios of SRRK and CCCC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SRRKCCCCDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.43

1.07

-0.64

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.05

-0.33

+0.38

Sharpe Ratio (All Time)

Calculated using the full available price history

0.09

-0.26

+0.35

Drawdowns

SRRK vs. CCCC - Drawdown Comparison

The maximum SRRK drawdown since its inception was -93.15%, roughly equal to the maximum CCCC drawdown of -97.82%. Use the drawdown chart below to compare losses from any high point for SRRK and CCCC.


Loading charts...

Drawdown Indicators


SRRKCCCCDifference

Max Drawdown

Largest peak-to-trough decline

-93.15%

-97.82%

+4.67%

Max Drawdown (1Y)

Largest decline over 1 year

-34.86%

-52.10%

+17.24%

Max Drawdown (3Y)

Largest decline over 3 years

-65.21%

-90.00%

+24.79%

Max Drawdown (5Y)

Largest decline over 5 years

-88.96%

-97.82%

+8.86%

Current Drawdown

Current decline from peak

-35.61%

-92.89%

+57.28%

Average Drawdown

Average peak-to-trough decline

-56.44%

-71.93%

+15.49%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.61%

26.91%

-12.30%

Volatility

SRRK vs. CCCC - Volatility Comparison

The current volatility for Scholar Rock Holding Corporation (SRRK) is 13.58%, while C4 Therapeutics, Inc. (CCCC) has a volatility of 33.23%. This indicates that SRRK experiences smaller price fluctuations and is considered to be less risky than CCCC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SRRKCCCCDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.58%

33.23%

-19.65%

Volatility (6M)

Calculated over the trailing 6-month period

35.86%

64.03%

-28.17%

Volatility (1Y)

Calculated over the trailing 1-year period

65.55%

101.70%

-36.15%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

180.23%

117.54%

+62.69%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

157.72%

113.15%

+44.57%

Dividends

SRRK vs. CCCC - Dividend Comparison

Neither SRRK nor CCCC has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

SRRK vs. CCCC - Financials Comparison

This section allows you to compare key financial metrics between Scholar Rock Holding Corporation and C4 Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M30.00M35.00M2022202320242025202600
(SRRK) Total Revenue
(CCCC) Total Revenue
Values in USD except per share items

Frequently Asked Questions


SRRK and CCCC have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CCCC has higher volatility (33.23%) compared to SRRK (13.58%). In terms of maximum drawdown, SRRK dropped -93.15% vs CCCC's -97.82%.

CCCC currently has the higher Sharpe Ratio (1.07 vs 0.43), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SRRK and CCCC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer